Incyte Stock: Is Wall Street Bullish or Bearish?

With a market cap of $25 billion, Incyte Corporation (INCY) is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapeutics across the United States, Europe, Canada, and Japan. It markets a diverse portfolio of oncology, immunology, and dermatology medicines, including JAKAFI, OPZELURA, and ICLUSIG.

Shares of the Wilmington, Delaware-based company have outperformed the broader market over the past 52 weeks. INCY stock has soared 42.1% over this time frame, while the broader S&P 500 Index ($SPX) has gained 20.1%. Moreover, the stock has increased 25% on a YTD basis, compared to SPX's 13.1% return.